Head-to-head · Cost-Efficiency Index
Invigor Medical vs Lttl
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invigor Medical
Value shoppers who want competitive pricing on both molecules plus a wider wellness/hormone program on one account.
Visit Invigor MedicalLttl
Shoppers who want every commitment tier priced openly, plus a low-dose microdose option.
Visit LttlThe verdict
Invigor Medical takes it, leading the Cost-Efficiency Index 88 to 64. Solid mid-market cost on both molecules from an established operator — good value if you also want a broader metabolic and hormone catalog. Lttl still earns a C — Shoppers who want every commitment tier priced openly, plus a low-dose microdose option.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Invigor Medical.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invigor Medical | Lttl |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 64/100 |
| Semaglutide / mo | $199/mo | $199/mo (all doses, compounded) |
| Tirzepatide / mo | $339/mo | $279/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | $2,388 | $2,388 |
| Tirzepatide / yr (modeled) | $4,068 | $3,348 |
| Coverage | Not disclosed | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank on the board | #8 | #175 |
Invigor Medical
88/100Where the value is
- Competitive mid-market pricing on both semaglutide and tirzepatide
- Long-running operator with a broad catalog that can consolidate spend
- Both molecules published up front for easy cost modeling
The tradeoffs
- Does not publish an explicit states-served list, so access is a variable in the model
- Compounded only
Lttl
64/100Where the value is
- Publishes the full price matrix — every medication, form and commitment length — on a public /plans page before checkout
- Flat dose pricing: 'Same price at every dose,' so moving to a higher dose does not raise the monthly bill
- States plainly that its compounded GLP-1s 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
The tradeoffs
- Partner pharmacies are never named — the site refers only to 'a partner U.S. pharmacy' (a material disclosure gap for a YMYL purchase)
- The advertised 'Plans start at $129/mo' is the 12-month prepay rate; true month-to-month is $199 semaglutide and $279 tirzepatide
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.